Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
The effect of different doses of 5-aza-2'-deoxycytidine (5-aza-dCyd) or cytarabine (ara-C) on the survival time of mice with intracerebral (ic) L1210 leukemia was compared. CD2F1 mice were given ic inoculation of 10(3) L1210 cells, and chemotherapy was given as a 12-hour iv infusion at various days thereafter. Treatment on Day 6 with increasing doses of 5-aza-dCyd reached a mean maximal percent increase in lifespan (ILS) of 118% at 20 mg/kg, whereas the mean maximal ILS reached for ara-C was about 60% at 1000 mg/kg. When these equitoxic doses of each drug, as determined by body weight loss, were given on Day 3, 4, or 5, 5-aza-dCyd gave greater ILS and more 60-day survivors than ara-C. These data indicate that 5-aza-dCyd is more effective than ara-C against the ic L1210 leukemia.
D000818:Animals; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy*; D003561:Cytarabine / Q000627:therapeutic use*; D000077209:Decitabine; D004305:Dose-Response Relationship, Drug; D007700:Kinetics; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains
D003561:Cytarabine; D000077209:Decitabine; D001374:Azacitidine